180 related articles for article (PubMed ID: 30971660)
1. [Pharmacological and clinical effects of letermovir (Prevymis
Ogawa M; Eto T
Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
[TBL] [Abstract][Full Text] [Related]
4. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
Goldner T; Hempel C; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2014; 58(1):610-3. PubMed ID: 24189264
[TBL] [Abstract][Full Text] [Related]
5. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
7. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
8. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
10. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.
Goldner T; Hewlett G; Ettischer N; Ruebsamen-Schaeff H; Zimmermann H; Lischka P
J Virol; 2011 Oct; 85(20):10884-93. PubMed ID: 21752907
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Lischka P; Michel D; Zimmermann H
J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
[TBL] [Abstract][Full Text] [Related]
12. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
13. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.
Chou S
Antiviral Res; 2017 Dec; 148():1-4. PubMed ID: 29107686
[TBL] [Abstract][Full Text] [Related]
14. Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
Lischka P; Zhang D; Holder D; Zimmermann H
Antiviral Res; 2016 Aug; 132():204-9. PubMed ID: 27345658
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Piret J; Goyette N; Boivin G
Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
[TBL] [Abstract][Full Text] [Related]
16. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Razonable RR
Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
[TBL] [Abstract][Full Text] [Related]
17. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
18. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.
Stoelben S; Arns W; Renders L; Hummel J; Mühlfeld A; Stangl M; Fischereder M; Gwinner W; Suwelack B; Witzke O; Dürr M; Beelen DW; Michel D; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Budde K
Transpl Int; 2014 Jan; 27(1):77-86. PubMed ID: 24164420
[TBL] [Abstract][Full Text] [Related]
19. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
20. Letermovir for the management of cytomegalovirus infection.
Bowman LJ; Melaragno JI; Brennan DC
Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
